Last checked at 
(Alliance News) - Baillie Gifford Japan and Fidelity Japan had a good month of September amid easing US-China trade tensions and rising monetary stimulus hopes, Quoteddata said on Tuesday.
Last week, Japan Prime Minister Shinzo Abe said the government was ready to take precautions if risks to the economy intensified, signaling a stimulus boost in the event that October's sales tax hike triggers a sharp downturn in growth.
Further, at its meeting last month the Bank of Japan kept monetary policy steady but indicated its willingness to expand monetary stimulus as early as its October 30-31 meeting in a bid to sustain economic growth.
The Japanese economy has been hurt by the protracted trade spat between the US and China.
Conversely, Woodford Patient Capital Trust's woes continued after the trust reported a sharp decline in net asset value in the first half.
At the beginning of June, Neil Woodford took the decision to suspend withdrawals from his equity income fund due to "an increased level of redemptions", with the fund needing time to "reposition" its portfolio invested in unquoted and less liquid stocks into more liquid investments.
Since then, the investor has made numerous disposals of stakes in London-listed firms.
Woodford Patient Capital Trust was demoted from the FTSE 250 in September, as part of the quarterly FTSE Russell index review changes.
The following were the best and worst performing London-listed investment companies in September:
| Best performing funds in NAV terms | % change on month | |
| Oakley Capital | 14.1 | |
| HgCapital | 14.1 | |
| Baillie Gifford Japan | 9.6 | |
| Weiss Korea Opportunity | 9.5 | |
| Aurora | 9.4 | |
| Aberdeen Standard Equity Income | 7.8 | |
| Temple Bar IT | 7.5 | |
| Gresham House Strategic | 7.4 | |
| Fidelity Japan | 7.3 | |
| Perpetual Income & Growth | 7.3 | |
| Worst performing funds in NAV terms | % change on month | |
| Woodford Patient Capital | -13.5 | |
| Biotech Growth | -12.3 | |
| Marwyn Value Investors | -11.5 | |
| Golden Prospect Precious Metal | -10.1 | |
| Carador Income USD | -9.4 | |
| Baillie Gifford US Growth | -8.0 | |
| Marble Point Loan Financing | -7.2 | |
| Blue Planet | -6.7 | |
| Worldwide Healthcare | -6.2 | |
| Allianz Technology | -5.7 | |
| Best performing funds in price terms | % change on month | |
| CATCo Reinsurance Opportunities | 29.4 | |
| Leaf Clean Energy | 20.8 | |
| CIP Merchant Capital | 16.7 | |
| Triple Point Social Housing REIT | 11.7 | |
| Ashoka India | 10.3 | |
| UIL Finance | 9.7 | |
| Woodford Patient Capital Trust | 9.2 | |
| EPE Special Opportunities | 8.6 | |
| BMO Commercial Property | 8.6 | |
| Schroder UK Mid Cap | 8.4 | |
| Worst performing funds in price terms | % change on month | |
| -15.5 | |
| Better Capital PCC 2012 | -12.8 | |
| BH Macro | -11.7 | |
| Baillie Gifford US Growth | -10.3 | |
| Golden Prospect Precious Metal | -10.1 | |
| Biotech Growth | -9.8 | |
| Scotgems | -9.2 | |
| RDL Realisation | -8.8 | |
| Reconstruction Capital II | -8.1 | |
| DP Aircraft I | -8.0 |
Source: QuotedData. Full details at www.quoteddata.com
Copyright 2019 Alliance News Limited. All Rights Reserved.
